Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

COGTCogent Biosciences, Inc.Signing up patients

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Advanced Gastrointestinal Stromal Tumors · Metastatic Cancer

10Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • Main results were due Sep 2025, none posted yet

    Counts until it's fixed

    +10
Worry score10

Score over time

Stage
Phase 3
Patients
482 (planned)
Started
Apr 14, 2022
Main results expected
Sep 30, 2025
Fully finished
Jan 2030
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Part 1a - pharmacokinetics - Cmax

    Measured over: 16 days

  • Part 1a - pharmacokinetics - AUC

    Measured over: 16 days

  • Part 1b - pharmacokinetics - Cmax

    Measured over: 14 days

  • Part 1b - pharmacokinetics - AUC

    Measured over: 14 days

  • Part 1b - pharmacokinetics - Tmax

    Measured over: 14 days

  • Part 2 - Progression Free Survival (PFS)

    Measured over: Approximately 48 months

  • DDI Substudy - pharmacokinetics - AUC

    Measured over: 16 days

  • DDI Substudy - pharmacokinetics - Cmax

    Measured over: 14 days

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • results_overdue: base 10, now 10, since 2025-09-30, no fading

Raw record changes

  • none yet

Trial ID NCT05208047 · record last updated 2026-06-16 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT05208047) ↗